BRPI0517232A - composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade

Info

Publication number
BRPI0517232A
BRPI0517232A BRPI0517232-2A BRPI0517232A BRPI0517232A BR PI0517232 A BRPI0517232 A BR PI0517232A BR PI0517232 A BRPI0517232 A BR PI0517232A BR PI0517232 A BRPI0517232 A BR PI0517232A
Authority
BR
Brazil
Prior art keywords
obesity
diabetes
pharmaceutically acceptable
therapeutic
hydrogen
Prior art date
Application number
BRPI0517232-2A
Other languages
English (en)
Inventor
Noriaki Hashimoto
Keiji Takahashi
Fumiko Sakai
Teruyuki Nishimura
Chisato Nakama
Jun-Ichi Eiki
Yoshio Ogino
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of BRPI0517232A publication Critical patent/BRPI0517232A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO FARMACêUTICA, ATIVADOR DA GLICOCINASE, E, AGENTES TERAPêUTICOS E/OU PROFILáTICOS PARA DIABETES E PARA OBESIDADE. Compostos representados pela fórmula geral (I), ou seus sais farmaceuticamente aceitáveis, que têm atividade ativadora da glicocinase e são úteis como agentes terapêuticos para diabetes e obesidade: em que R¬ 1¬ e R¬ 2¬ são cada um hidrogênio ou similar; R¬ 3¬ é hidrogênio, halogênio ou similar; R¬ 4¬ é hidrogênio, alquila inferior ou similar; Q é um carbono, nitrogênio ou átomo de enxofre (com a condição de que o átomo de enxofre possa ser mono ou di-substituído por oxo); R¬ 5¬ e R¬ 6¬ são cada um hidrogênio, alquila inferior, ou similar; X˜, X, X e X¬ 4¬ são, cada um independentemente, carbono ou nitrogênio; Z é oxigênio, enxofre ou nitrogênio; Ar é arila ou heteroarila; A é um grupo heterocíclico aromático nitrogenoso de 5 ou 6 membros; m é um inteiro de 1 a 6; n é um inteiro de 0 a 3; p é um inteiro de 0 a 2 (com a condição de que pelo menos dois de X˜ a X¬ 4¬ sejam cada um carbono); e q é 0 ou 1.
BRPI0517232-2A 2004-11-02 2005-11-01 composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade BRPI0517232A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004319339 2004-11-02
JP2005178628 2005-06-17
PCT/JP2005/020483 WO2006049304A1 (ja) 2004-11-02 2005-11-01 アリールオキシ置換ベンズイミダゾール誘導体

Publications (1)

Publication Number Publication Date
BRPI0517232A true BRPI0517232A (pt) 2008-10-07

Family

ID=36319300

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517232-2A BRPI0517232A (pt) 2004-11-02 2005-11-01 composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade

Country Status (17)

Country Link
US (1) US7932394B2 (pt)
EP (1) EP1810969B1 (pt)
JP (1) JP5036316B2 (pt)
KR (1) KR20070083939A (pt)
CN (1) CN101094847B (pt)
AU (1) AU2005301608B2 (pt)
BR (1) BRPI0517232A (pt)
CA (1) CA2586056C (pt)
CR (1) CR9078A (pt)
EC (1) ECSP077422A (pt)
IL (1) IL182679A0 (pt)
MA (1) MA29043B1 (pt)
MX (1) MX2007005289A (pt)
NO (1) NO20072806L (pt)
NZ (1) NZ554440A (pt)
RU (1) RU2398773C2 (pt)
WO (1) WO2006049304A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063738A1 (ja) * 2003-12-29 2005-07-14 Banyu Pharmaceutical Co.,Ltd 新規２－へテロアリール置換ベンズイミダゾール誘導体
AU2006267338B2 (en) 2005-07-13 2012-08-16 Msd K.K. Heterocycle-substituted benzimidazole derivative
JP2009519308A (ja) * 2005-12-15 2009-05-14 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2377863A1 (en) 2007-01-04 2011-10-19 Prosidion Limited Piperidine GPCR agonists
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AU2008321959B2 (en) 2007-11-12 2014-02-13 Msd K.K. Heteroaryloxy quinazoline derivative
JP5623289B2 (ja) 2007-12-19 2014-11-12 ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
RU2450001C2 (ru) 2007-12-20 2012-05-10 Эл Джи Лайф Сайенсиз Лтд. Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента
JP2012500181A (ja) 2008-08-15 2012-01-05 Ｍｓｄ株式会社 アセチルピロリジニルインドール誘導体
WO2010024110A1 (en) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co.,Ltd. Oxotetrahydrofuran-2-yl-benzimidazole derivative
CN101607923B (zh) * 2009-07-21 2012-12-19 焦宁 芳基腈类化合物或其衍生物及其合成方法和应用
SG190784A1 (en) * 2010-11-09 2013-07-31 Fujian Haixi Pharmaceuticals Inc Compound for increasing kinase active and application thereof
US20120258891A1 (en) * 2011-04-07 2012-10-11 Nimblegen Systems Gmbh Diarylsulfide backbone containing photolabile protecting groups
WO2015161016A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Bicyclic cgrp receptor antagonists
JP6898340B2 (ja) * 2015-11-17 2021-07-07 コルテバ アグリサイエンス エルエルシー ４−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１ｈ−１，２，４−トリアゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）ベンゾニトリル及び調製方法
EP3376865B1 (en) * 2015-11-17 2021-04-14 Dow Agrosciences LLC 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h
JP6987070B2 (ja) * 2015-11-17 2021-12-22 コルテバ アグリサイエンス エルエルシー ４−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−オキソエチル）ピリジン−３−イル）オキシ）ベンゾニトリル及び製造方法
AU2018208458B2 (en) * 2017-01-10 2020-07-16 ETH Zürich Cell-protective compounds and their use
WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
WO2024033677A1 (en) * 2022-08-09 2024-02-15 Faculdade De Farmácia Da Universidade De Lisboa One-pot method for the synthesis of 3-acetamido-furfural from n-acetylglucosamine
JP7356203B1 (ja) 2023-08-03 2023-10-04 Ｔｏｗａ Ｃｏｒｐｏｒａｔｉｏｎ 株式会社 ＷＤ ａｎｄ ｔｅｔｒａｔｒｉｃｏｐｅｐｔｉｄｅ ｒｅｐｅａｔｓ １遺伝子発現亢進用医薬組成物及び食品組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DK337086A (da) * 1985-08-12 1987-02-13 Hoffmann La Roche Benzimidazolderivater
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US20020032330A1 (en) 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
JPH10306076A (ja) 1997-03-06 1998-11-17 Nippon Chemiphar Co Ltd プロピオン酸誘導体
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2282299T3 (es) 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
BR0115999A (pt) 2000-12-06 2003-09-30 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2004123711A (ja) 2002-08-02 2004-04-22 Sankyo Co Ltd レゾルシノール誘導体
WO2004013109A1 (ja) 2002-08-02 2004-02-12 Sankyo Company, Limited レゾルシノール誘導体
JP2004067629A (ja) 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
JP4400563B2 (ja) 2003-02-13 2010-01-20 萬有製薬株式会社 新規２−ピリジンカルボキサミド誘導体
WO2005063738A1 (ja) * 2003-12-29 2005-07-14 Banyu Pharmaceutical Co.,Ltd 新規２－へテロアリール置換ベンズイミダゾール誘導体

Also Published As

Publication number Publication date
EP1810969A1 (en) 2007-07-25
AU2005301608A1 (en) 2006-05-11
RU2007120519A (ru) 2008-12-10
EP1810969B1 (en) 2013-08-07
CR9078A (es) 2007-10-01
RU2398773C2 (ru) 2010-09-10
NO20072806L (no) 2007-07-27
US7932394B2 (en) 2011-04-26
JPWO2006049304A1 (ja) 2008-05-29
EP1810969A4 (en) 2011-05-25
CN101094847A (zh) 2007-12-26
CN101094847B (zh) 2011-06-15
AU2005301608B2 (en) 2012-09-13
CA2586056C (en) 2012-03-13
MX2007005289A (es) 2007-07-19
JP5036316B2 (ja) 2012-09-26
WO2006049304A1 (ja) 2006-05-11
ECSP077422A (es) 2007-05-30
MA29043B1 (fr) 2007-11-01
US20080125429A1 (en) 2008-05-29
KR20070083939A (ko) 2007-08-24
NZ554440A (en) 2010-01-29
IL182679A0 (en) 2007-09-20
CA2586056A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0517232A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
BRPI0407283A (pt) Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
BR0010391A (pt) Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto
UA97257C2 (en) Indole derivatives
WO2005097129A3 (en) 6-azaindole compound
TW200716528A (en) Cyclopropanecarboxamide derivatives
SG163617A1 (en) Macrocyclic inhibitors of hepatitis c virus
BR112012026948A2 (pt) composto, composição farmacêutica, e, métodos para melhorar o metabolismo ósseo, para previnir ou tratar uma doença associada com metabolismo ósseo e para previnir ou tratar osteoporose.
BR112012016111A2 (pt) Composto hererocíclico contendo nitrogênio, fungicida agrícola, e, produto intermediário
MX344669B (es) Agente antiplaquetas novedoso.
BRPI0518651A2 (pt) composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes
ATE433981T1 (de) Heterocyclische verbindungen
NO20073325L (no) Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
MY177250A (en) Novel nicotinamide derivative or salt thereof
NO20066015L (no) Fuserte heterosykliske forbindelser
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
MX2009013728A (es) Derivados de bicicloanilina.
TW200633991A (en) Chemical compounds
PL1819686T3 (pl) Pochodne 5-hydroksy-benzotiazolu o aktywności agonistów beta-2-adrenoreceptora
MX339668B (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
NO20062533L (no) 5-fluor, 5-klor- og cyanopyridin-2-yl-tetrazoler som ligander for den metabotrofe glutamatreseptor-5
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
BRPI0719869A2 (pt) Composto ou um sal do mesmo, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono em uma mamífero, e, uso do composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2210 DE 14/05/2013.